Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Abbott Laboratories, liquidity ratios (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


The analysis of the liquidity ratios over the reported periods indicates varying trends in the company's short-term financial health and its ability to cover current liabilities.

Current Ratio
The current ratio shows a general upward trend from March 31, 2020 (1.43) to peak at around mid-2022 (2.01 on June 30, 2022). This suggests an improvement in the company's ability to meet its short-term obligations during this period. However, after mid-2022, there is a noticeable decline with fluctuations, dropping to 1.63 by December 31, 2022, followed by moderate oscillations but generally remaining above 1.6 through June 30, 2025. This pattern may imply a period of stabilization after initial growth in liquidity, maintaining a reasonable buffer over the subsequent periods.
Quick Ratio
The quick ratio progressively increased from 0.83 in March 31, 2020, reaching its highest point around June 30, 2022 (1.33), which reflects an increasing capacity to cover current liabilities with more liquid assets, excluding inventory. Post-June 2022, the ratio exhibits some volatility with a downward movement toward 1.00 by late 2023 and early 2024, suggesting a slight tightening in liquidity. It recovers slightly toward mid-2025, ending at 1.14. The trend indicates fluctuating but overall adequate liquid asset coverage during the examined timeframe.
Cash Ratio
The cash ratio rose from 0.34 on March 31, 2020, to a peak of 0.78 by December 31, 2021, which signals a strengthening in immediately available cash and cash equivalents relative to current liabilities. However, starting from early 2022, the cash ratio declines and then stabilizes between 0.47 and 0.66 over the subsequent quarters, with some minor fluctuations. Toward the end of the data series, slight increases are observed bringing the ratio to approximately 0.54 by June 30, 2025. This reflects a more conservative cash holding pattern, possibly balancing between liquidity management and operational investment needs.

In summary, all three liquidity ratios indicate an initial improvement in short-term financial strength until around mid-2022, followed by moderated fluctuations and stabilization. The current and quick ratios demonstrate the company generally maintains a solid liquidity position, comfortably above the critical threshold of 1. The cash ratio reveals that while cash reserves increased early in the period, the company later maintained a more moderate cash level relative to liabilities, potentially optimizing cash use without compromising liquidity.


Current Ratio

Abbott Laboratories, current ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals notable patterns and fluctuations in the liquidity position as indicated by current assets, current liabilities, and the current ratio over the periods presented.

Current Assets
Current assets exhibited an overall increasing trend from March 31, 2020, ($15,498 million) to December 31, 2020, ($20,441 million), indicating enhanced liquidity. This upward trend continued, reaching a peak around June 30, 2022 ($24,956 million). Subsequently, there was a moderate decline and fluctuation, with values ranging mostly within $22,000 million to $24,500 million through the end of the dataset in June 30, 2025 ($24,468 million). The data imply some volatility in current assets levels during the latter periods but generally sustained elevated levels relative to the early quarters.
Current Liabilities
Current liabilities showed a gradual increase from March 31, 2020, ($10,808 million) to a peak around December 31, 2022 ($15,489 million). Following this peak, liabilities experienced a gradual reduction toward the mid-2025 period, falling to $13,439 million by June 30, 2025. Although there is an increase initially, the later periods reflect a downward adjustment in liabilities, which may mitigate financial risk associated with short-term obligations.
Current Ratio
The current ratio followed an upward trajectory from 1.43 in March 2020 to a high of approximately 2.01 in June 2022, indicating an improvement in the company's ability to cover short-term liabilities with current assets. Thereafter, the ratio dipped to a low of 1.60 at various points but remained generally stable and above 1.6, finishing near 1.82 in June 2025. This pattern suggests that although the liquidity margin narrowed after mid-2022, the company's short-term financial health remained solid throughout the period.

In summary, the data indicate an overall strengthening of liquidity through mid-2022, characterized by rising current assets and an increasing current ratio despite growing liabilities. Post mid-2022, although current liabilities decreased, a modest contraction in current assets led to a slight decline in the current ratio, signaling a stabilization rather than a deterioration in liquidity. The company's ability to meet short-term obligations has remained consistently adequate, with the current ratio well above 1.5 for most of the observed period.


Quick Ratio

Abbott Laboratories, quick ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Trade receivables, less allowances
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The analyzed data reveals several notable trends related to the liquidity position and current obligations over the observed periods.

Total quick assets
The total quick assets generally exhibit a rising trend from March 2020 through December 2021, peaking around the 16,700 million US dollar range. After this peak, there is a gradual decline observed from early 2022 to late 2023, followed by a fluctuating pattern with a modest recovery toward 15,000 million US dollars near mid-2025.
Current liabilities
Current liabilities show relatively less volatility but an overall upward movement from March 2020 through December 2022, reaching nearly 15,500 million US dollars at their highest. Subsequently, a decline is observed from early 2023 through mid-2025, falling to approximately 13,400 million US dollars.
Quick ratio
The quick ratio demonstrates an improving liquidity situation from below 1.0 in early 2020 to a peak above 1.2 by the end of 2021. This indicates the company increased its ability to cover current liabilities with its quick assets during this period. Thereafter, the quick ratio declines slightly around 2022 and 2023, stabilizing close to 1.0, and then shows a mild upward trend again toward 1.14 by mid-2025.

In summary, the period from 2020 to 2021 reflects a strengthening liquidity position as evidenced by growing quick assets and current liabilities with an improving quick ratio. Later periods suggest heightened variability in quick assets and a reduction in current liabilities, leading to a more balanced but somewhat lower quick ratio. The quick ratio remaining near or above 1.0 in recent quarters implies that quick assets are generally sufficient to meet current liabilities, maintaining an acceptable short-term financial health status.


Cash Ratio

Abbott Laboratories, cash ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


Total Cash Assets
The total cash assets exhibit notable fluctuations across the observed periods. Starting at 3,668 million US dollars in the first quarter of 2020, there is a general upward trend culminating at a peak of 10,249 million US dollars by the end of 2021. Subsequent quarters reveal a decline, with cash assets decreasing to 7,047 million by the third quarter of 2023, before showing some recovery towards the end of 2024 and 2025, ending at 7,282 million. This indicates a cycle of accumulation of cash assets followed by drawdowns and partial replenishments in later periods.
Current Liabilities
Current liabilities have a generally increasing trajectory throughout the timeline. Beginning at 10,808 million US dollars in the first quarter of 2020, liabilities grow steadily, reaching 15,489 million in the fourth quarter of 2022. After this peak, current liabilities experience some volatility but mostly remain elevated, fluctuating between 13,004 and 14,439 million towards the middle of 2025. This trend reflects an increasing short-term financial obligation load over the periods, with peak pressure around late 2022.
Cash Ratio
The cash ratio, which measures liquidity by comparing cash assets to current liabilities, shows a marked improvement from 0.34 at the beginning of 2020 to a high of 0.78 by the end of 2021. This increase corresponds to the earlier noted rise in cash assets relative to liabilities. However, from 2022 onwards, the cash ratio declines and stabilizes in the range of approximately 0.47 to 0.56 through the first half of 2025. This decline suggests relatively tighter liquidity conditions despite occasional recoveries, consistent with the downward trend in cash assets and fluctuations in current liabilities in the later periods.
Overall Patterns and Insights
The data indicate that liquidity strengthened considerably through 2020 and 2021, supported by rising cash assets outpacing liabilities. Post-2021, liquidity ratios and cash levels trended downward, reflecting increased current liabilities and reductions in cash holdings. The company appears to manage its short-term liabilities with moderate liquidity buffers, though the decreasing cash ratio towards the later periods signals more conservative cash reserves in relation to current obligations. These shifts may suggest strategic deployment of cash resources or changes in operating conditions influencing working capital management.